SanBio Company Limited Logo

SanBio Company Limited

SNBIF

(0.8)
Stock Price

5,81 USD

-49.42% ROA

-100.25% ROE

-18.06x PER

Market Cap.

39.169.824.146,43 USD

24.92% DER

0% Yield

0% NPM

SanBio Company Limited Stock Analysis

SanBio Company Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

SanBio Company Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (23%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-169.3%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-98.97%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's elevated P/BV ratio (9.95x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

SanBio Company Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

SanBio Company Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Buy

SanBio Company Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

SanBio Company Limited Revenue
Year Revenue Growth
2014 204.286.000
2015 3.229.211.000 93.67%
2016 1.174.644.000 -174.91%
2017 949.543.000 -23.71%
2018 490.509.000 -93.58%
2019 741.614.000 33.86%
2020 447.226.000 -65.83%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%
2024 0 0%
2025 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

SanBio Company Limited Research and Development Expenses
Year Research and Development Expenses Growth
2014 530.277.000
2015 623.415.000 14.94%
2016 1.695.792.000 63.24%
2017 2.058.346.000 17.61%
2018 4.156.101.000 50.47%
2019 3.721.042.000 -11.69%
2020 4.327.729.000 14.02%
2021 4.071.641.000 -6.29%
2022 4.955.385.000 17.83%
2023 6.118.125.000 19%
2024 4.195.096.000 -45.84%
2024 2.849.590.000 -47.22%
2025 1.548.404.000 -84.03%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

SanBio Company Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2014 258.251.000
2015 357.048.000 27.67%
2016 604.095.000 40.9%
2017 806.257.000 25.07%
2018 712.790.000 -13.11%
2019 754.492.000 5.53%
2020 1.605.566.000 53.01%
2021 1.730.098.000 7.2%
2022 1.665.498.000 -3.88%
2023 1.781.183.000 6.49%
2024 1.652.184.000 -7.81%
2024 0 0%
2025 1.117.928.000 100%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

SanBio Company Limited EBITDA
Year EBITDA Growth
2014 -581.441.000
2015 2.239.591.000 125.96%
2016 -1.140.139.000 296.43%
2017 -2.126.911.000 46.39%
2018 -3.868.032.000 45.01%
2019 -2.849.226.000 -35.76%
2020 -5.059.544.000 43.69%
2021 -6.408.792.000 21.05%
2022 -4.531.133.000 -41.44%
2023 -4.648.983.000 2.53%
2024 -3.739.064.000 -24.34%
2024 -4.525.225.000 17.37%
2025 -2.656.564.000 -70.34%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

SanBio Company Limited Gross Profit
Year Gross Profit Growth
2014 204.286.000
2015 3.229.211.000 93.67%
2016 1.174.644.000 -174.91%
2017 932.375.000 -25.98%
2018 490.509.000 -90.08%
2019 741.614.000 33.86%
2020 447.226.000 -65.83%
2021 -74.455.000 700.67%
2022 -132.467.000 43.79%
2023 -24.615.000 -438.16%
2024 0 0%
2024 -14.504.000 100%
2025 -9.768.000 -48.48%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

SanBio Company Limited Net Profit
Year Net Profit Growth
2014 -589.454.000
2015 1.736.265.000 133.95%
2016 -988.397.000 275.66%
2017 -1.835.296.000 46.15%
2018 -3.940.327.000 53.42%
2019 -2.920.563.000 -34.92%
2020 -5.157.716.000 43.37%
2021 -3.385.875.000 -52.33%
2022 -4.677.856.000 27.62%
2023 -5.559.584.000 15.86%
2024 -2.504.644.000 -121.97%
2024 -2.644.332.000 5.28%
2025 -579.400.000 -356.39%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

SanBio Company Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2014 -15
2015 44 134.09%
2016 -23 300%
2017 -41 45%
2018 -87 53.49%
2019 -60 -43.33%
2020 -101 40%
2021 -65 -53.85%
2022 -90 27.78%
2023 -96 5.26%
2024 -39 -150%
2024 -40 5%
2025 -8 -400%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

SanBio Company Limited Free Cashflow
Year Free Cashflow Growth
2014 -121.618.000
2015 -221.609.000 45.12%
2016 -1.422.178.000 84.42%
2017 -1.893.538.000 24.89%
2018 -1.939.266.000 2.36%
2019 -3.974.701.000 51.21%
2020 -5.824.240.000 31.76%
2021 -5.354.443.000 -8.77%
2022 -6.602.741.000 18.91%
2023 -7.442.150.000 11.28%
2024 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

SanBio Company Limited Operating Cashflow
Year Operating Cashflow Growth
2014 -111.534.000
2015 -218.504.000 48.96%
2016 -1.362.083.000 83.96%
2017 -1.796.175.000 24.17%
2018 -1.906.769.000 5.8%
2019 -3.968.342.000 51.95%
2020 -5.717.292.000 30.59%
2021 -5.215.683.000 -9.62%
2022 -6.546.664.000 20.33%
2023 -7.434.147.000 11.94%
2024 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

SanBio Company Limited Capital Expenditure
Year Capital Expenditure Growth
2014 10.084.000
2015 3.105.000 -224.77%
2016 60.095.000 94.83%
2017 97.363.000 38.28%
2018 32.497.000 -199.61%
2019 6.359.000 -411.04%
2020 106.948.000 94.05%
2021 138.760.000 22.93%
2022 56.077.000 -147.45%
2023 8.003.000 -600.7%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

SanBio Company Limited Equity
Year Equity Growth
2014 -1.962.838.000
2015 -87.296.000 -2148.49%
2016 6.366.508.000 101.37%
2017 4.594.998.000 -38.55%
2018 853.250.000 -438.53%
2019 8.909.120.000 90.42%
2020 10.930.183.000 18.49%
2021 8.349.923.000 -30.9%
2022 2.035.135.000 -310.29%
2023 4.428.909.000 54.05%
2024 3.839.920.000 -15.34%
2024 2.792.398.000 -37.51%
2025 2.399.672.000 -16.37%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

SanBio Company Limited Assets
Year Assets Growth
2014 474.400.000
2015 1.755.057.000 72.97%
2016 8.271.017.000 78.78%
2017 6.292.414.000 -31.44%
2018 5.193.554.000 -21.16%
2019 13.975.975.000 62.84%
2020 15.605.414.000 10.44%
2021 13.343.826.000 -16.95%
2022 5.510.901.000 -142.14%
2023 7.045.114.000 21.78%
2024 5.932.036.000 -18.76%
2024 5.047.291.000 -17.53%
2025 4.420.738.000 -14.17%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

SanBio Company Limited Liabilities
Year Liabilities Growth
2014 2.437.238.000
2015 1.842.353.000 -32.29%
2016 1.904.509.000 3.26%
2017 1.697.416.000 -12.2%
2018 4.340.304.000 60.89%
2019 5.066.855.000 14.34%
2020 4.675.231.000 -8.38%
2021 4.993.903.000 6.38%
2022 3.475.766.000 -43.68%
2023 2.616.205.000 -32.86%
2024 2.092.116.000 -25.05%
2024 2.254.892.000 7.22%
2025 2.021.065.000 -11.57%

SanBio Company Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-31.6
Price to Earning Ratio
-18.06x
Price To Sales Ratio
0x
POCF Ratio
1612.55
PFCF Ratio
1616.98
Price to Book Ratio
16.28
EV to Sales
0
EV Over EBITDA
-9.6
EV to Operating CashFlow
1478.3
EV to FreeCashFlow
1478.3
Earnings Yield
-0.06
FreeCashFlow Yield
0
Market Cap
39,17 Bil.
Enterprise Value
35,81 Bil.
Graham Number
157.9
Graham NetNet
28.29

Income Statement Metrics

Net Income per Share
-31.6
Income Quality
-9.16
ROE
-0.93
Return On Assets
-0.61
Return On Capital Employed
-1.04
Net Income per EBT
1.16
EBT Per Ebit
0.62
Ebit per Revenue
0
Effective Tax Rate
-0.16

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.35
Free CashFlow per Share
0.35
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-1.71
Return on Tangible Assets
-0.49
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
57,82
Book Value per Share
35,06
Tangible Book Value per Share
35.06
Shareholders Equity per Share
35.06
Interest Debt per Share
8.99
Debt to Equity
0.25
Debt to Assets
0.14
Net Debt to EBITDA
0.9
Current Ratio
8.54
Tangible Asset Value
2,36 Bil.
Net Current Asset Value
2,28 Bil.
Invested Capital
0.25
Working Capital
3,79 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

SanBio Company Limited Dividends
Year Dividends Growth

SanBio Company Limited Profile

About SanBio Company Limited

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.

CEO
Mr. Keita Mori MBA
Employee
29
Address
St. Luke Tower
Tokyo, 104-0044

SanBio Company Limited Executives & BODs

SanBio Company Limited Executives & BODs
# Name Age
1 Dr. Kazumi Sawaguchi Ph.D.
Corporate Officer and Head of Japan Regulatory Affairs & Quality Compliance Japan
70
2 Mr. Keizo Nakada
Corporate Officer & Head of Production
70
3 Mr. Naoki Tsukahara
Senior Corporate Officer
70
4 Mr. Dai Chida
Senior Scientific Advisor
70
5 Mr. Keita Mori MBA
Co-Founder, President, Executive Officer, Chief Executive Officer & Representative Director
70
6 Mr. Yoshihiro Kakutani
Corporate Officer of Management Administration
70
7 Mr. Shinya Hirata
Corporate Officer & Head of Research and Development
70
8 Mr. Toru Kawanishi
Co-Founder & Executive Chairman
70

SanBio Company Limited Competitors